Table 1 Prevalence of endocrine-related and other irAEs after treatment with various immune checkpoint inhibitors and percentage of primary disease.
Ipilimumab and PD-1 inhibitors (n = 26) | Nivolumab (n = 241) | Pembrolizumab (n = 190) | Atezolizumab (n = 95) | Dulbumumab (n = 15) | Avelumab (n = 4) | |
|---|---|---|---|---|---|---|
Any irAEs (%) | 80.8 | 47.3 | 53.7 | 59.0 | 26.7 | 50.0 |
Endocrine-related irAEs (%) | 50.0 | 32.0 | 33.7 | 34.7 | 13.3 | 50.0 |
Multiple endocrine-related irAEs (%) | 15.4 | 0.8 | 3.2 | 3.2 | 0 | 0 |
Thyroid-related irAEs (%) | 50.0 | 28.6 | 29.5 | 31.6 | 13.3 | 50.0 |
Adrenal-related irAEs (%) | 15.4 | 2.1 | 3.7 | 6.3 | 0 | 25.0 |
Pituitary-related irAEs (%) | 15.4 | 1.2 | 4.2 | 3.2 | 0 | 25.0 |
Insulin-dependent diabetes (%) | 0 | 0.8 | 1.6 | 0 | 0 | 0 |
Other irAEs (%) | 47.7 | 24.9 | 33.2 | 34.7 | 20.0 | 25.0 |
Interstitial pneumonia (%) | 19.2 | 12.0 | 12.6 | 4.2 | 13.3 | 0 |
Biliary tract disorders (%) | 3.9 | 0.8 | 3.7 | 1.1 | 0 | 0 |
Enterocolitis (%) | 19.2 | 2.9 | 5.3 | 8.4 | 0 | 0 |
Skin disorders (%) | 15.4 | 5.8 | 7.9 | 4.2 | 0 | 25.0 |
Renal tubular disorders (%) | 7.7 | 0.4 | 2.1 | 3.2 | 6.7 | 0 |
Other irAEs except for above (%) | 15.4 | 6.2 | 9.0 | 15.8 | 6.7 | 0 |
Endocrine-related and other irAE complications (%) | 26.9 | 9.5 | 13.2 | 10.5 | 6.7 | 25 |
Percentage of primary disease | ||||||
Non-small cell lung cancer (n = 179) (%) | 4.6 | 42.2 | 33.3 | 16.6 | 8.4 | 0 |
Gastrointestinal Tumors (n = 144) (%) | 0 | 91.7 | 8.3 | 0 | 0 | 0 |
Hepatocellular carcinoma (n = 44) (%) | 0 | 0 | 0 | 100 | 0 | 0 |
Otolaryngological tumors (n = 43) (%) | 3.9 | 62.8 | 37.2 | 0 | 0 | 0 |
Urothelial cancer (n = 42) (%) | 2.4 | 0 | 92.9 | 0 | 0 | 4.8 |
Malignant melanoma (n = 35) (%) | 28.6 | 40.0 | 31.4 | 0 | 0 | 0 |
Renal cell cancer (n = 27) (%) | 33.3 | 40.7 | 18.5 | 0 | 0 | 7.4 |
Small cell lung cancer (n = 23) | 0 | 0 | 0 | 100 | 0 | 0 |
Other tumors (n = 27) (%) | 3.7 | 33.3 | 48.1 | 14.8 | 0 | 0 |
Cancer of unknown primary (n = 7) (%) | 0 | 85.7 | 14.3 | 0 | 0 | 0 |
